| 0.7652 -0.023 (-2.87%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.06 | 1-year : | 1.24 |
| Resists | First : | 0.9 | Second : | 1.07 |
| Pivot price | 0.88 |
|||
| Supports | First : | 0.64 | Second : | 0.54 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.85  |
| MA(100) : | 0.76 |
MA(250) : | 0.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.7 |
D(3) : | 32.6 |
| RSI | RSI(14): 42.5 |
|||
| 52-week | High : | 1.7 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CTXR ] has closed above bottom band by 12.9%. Bollinger Bands are 114.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.8 | 0.8 - 0.81 |
| Low: | 0.73 - 0.74 | 0.74 - 0.75 |
| Close: | 0.75 - 0.77 | 0.77 - 0.78 |
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Thu, 11 Apr 2024
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with ... - PR Newswire
Thu, 04 Apr 2024
Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference - Longview News-Journal
Mon, 18 Mar 2024
Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for ... - PR Newswire
Wed, 14 Feb 2024
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the ... - PR Newswire
Wed, 14 Feb 2024
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update - PR Newswire
Tue, 13 Feb 2024
Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Path To Profitability - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 7.7 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 12,430 (K) |
| Shares Short P.Month | 11,860 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -41 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -2.95 |
| PEG Ratio | 0 |
| Price to Book value | 1.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|